Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Medical use  




2 Side effects  




3 Mechanism  




4 Synthesis  




5 References  













Cyamemazine






●العربية
 ●فارسی
 ●Français
 ●Polski
 ●Português
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Svenska
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  


Cyamemazine
Clinical data
Trade namesTercian
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, IM, IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability10-70%
MetabolismHepatic
Elimination half-life10 hours
ExcretionUrine
Identifiers

  • 10-(3-dimethylamino-2-methyl-propyl)phenothiazine-2-carbonitrile

CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.020.541 Edit this at Wikidata
Chemical and physical data
FormulaC19H21N3S
Molar mass323.46 g·mol−1
3D model (JSmol)

  • N#Cc2cc1N(c3c(Sc1cc2)cccc3)CC(C)CN(C)C

  • InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3 checkY

  • Key:SLFGIOIONGJGRT-UHFFFAOYSA-N checkY

 ☒NcheckY (what is this?)  (verify)

Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by TheraplixinFrance in 1972 and later in Portugal as well.[1][2][3][4]

Medical use[edit]

It is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.[5][6]

It is also used to reduce anxiety associated with benzodiazepine withdrawal syndrome and anxiety in depression with suicidal tendency.[7]

Side effects[edit]

Here are some of the most common side effects and related incidence:[8]

Mechanism[edit]

Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, H1, and mACh receptor antagonism,[9] it additionally produces potent blockade of several serotonin receptors, including 5-HT2A, 5-HT2C, and 5-HT7.[9][10][11][12] These actions have been implicated in cyamemazine's anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A),[9][10] and despite being classified as a typical antipsychotic, it actually behaves like an atypical antipsychotic.[13]

Site Ki (nM) Species Ref
H1 9.3 Guinea pig [14]
H2 351 Guinea pig [14]
H3 >10,000 Rat [14]
M1 13 Human [14]
M2 42 Human [14]
M3 32 Human [14]
M4 12 Human [14]
M5 35 Human [14]
5-HT1A 517 Human [14]
5-HT2A 1.5 Human [14]
5-HT2C 12 Human [14]
5-HT3 2,943 Human [14]
5-HT7 22 Human [14]
D1 3.8 Human [14]
D2 5.8 Human [14]
D3 2.5 Human [14]
D4 5.3 Human [14]
α1 2.3 Rat [14]
α2 1320 Rat [14]
GABAA >10,000 Rat [14]
GABAB >10,000 Rat [14]
Values are Ki (nM). The smaller the value,

the more strongly the drug binds to the site.

Synthesis[edit]

Synthesis:[15] Patent:[16]

2-Cyanophenothiazine [38642-74-9] (1) 3-Chloro-2-methylpropyl(dimethyl)amine [23349-86-2] (2)

References[edit]

  1. ^ Index Nominum, International Drug. Taylor & Francis. 2000. ISBN 978-3-88763-075-1.
  • ^ Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 534. ISBN 0-412-46630-9.
  • ^ Sittig M (January 1988). Pharmaceutical manufacturing ... - Google Books. Noyes Publications. ISBN 9780815511441.
  • ^ Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encephale (in French). 35 (2): 129–138. doi:10.1016/j.encep.2008.03.007. PMID 19393381. Archived from the original on 2013-02-13.
  • ^ "Cyamemazine". Stahl's Essential Psychopharmacology. Cambridge University Press.
  • ^ Bourin M, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169. S2CID 43312295.
  • ^ Benyamina A, Naassila M, Bourin M (July 2012). "Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal". Psychiatry Research. 198 (2). Elsevier BV: 307–312. doi:10.1016/j.psychres.2012.01.009. PMID 22421069. S2CID 34830082.
  • ^ Bourin M, Dailly E, Hascöet M (2006-06-07). "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews. 10 (3). Wiley: 219–229. doi:10.1111/j.1527-3458.2004.tb00023.x. PMC 6741725. PMID 15492772.
  • ^ a b c Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
  • ^ a b Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.
  • ^ Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology. 454 (2–3): 235–239. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
  • ^ Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology. 578 (2–3): 142–147. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
  • ^ Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–139. doi:10.1007/s00210-002-0665-4. PMID 12595954. S2CID 682064.
  • ^ a b c d e f g h i j k l m n o p q r s t u Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/s0006-2952(02)01515-0. PMID 12527336.
  • ^ Craig PN, Gordon M, Lafferty JJ, Lester BM, Saggiomo AJ, Zirkle CL (1961). "Synthesis of Phenothiazines. VI. Certain 2-Substituted Phenothiazines and Their 10-Aminoalkyl Derivatives". The Journal of Organic Chemistry. 26 (4): 1138–1143. doi:10.1021/jo01063a040.
  • ^ US 2877224, Jacob RM, Georges RJ gdate = 1959, assigned to Rhone Poulenc Sa 
    • Stub icon

    This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Cyamemazine&oldid=1193309760"
    Categories: 
    ●Alpha-1 blockers
     ●Dimethylamino compounds
     ●Dopamine antagonists
     ●H1 receptor antagonists
     ●Muscarinic antagonists
     ●Nitriles
     ●Phenothiazines
     ●Serotonin receptor antagonists
     ●Typical antipsychotics
     ●Psychoactive drug stubs
     Hidden categories: 
    ●CS1 French-language sources (fr)
     ●Articles with short description
     ●Short description is different from Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed DrugBank identifier
     ●Articles with changed EBI identifier
     ●ECHA InfoCard ID from Wikidata
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 3 January 2024, at 04:18 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki